Introducing... The FEnSI-23
We are excited to share a new, efficient, contemporary tool, the FEnSI-23 (FACT-Endometrial Symptom Index)! The FEnSI-23 assesses endometrial cancer patients’ symptoms and quality of life to support patients’ care.
This new instrument is a product of the PROMOTE (Patient-Reported Outcomes Measurement Opportunities Through Equity) study that asked endometrial cancer survivors their opinion on their quality of life and any symptoms from endometrial cancer and/or its treatment.
Upon completion of the PROMOTE Study, the research team published an academic manuscript in a special edition of Gynecologic Oncology on the development of the FEnSI-23. The study team also presented findings on the new measure and endometrial cancer survivorship challenges at the Society of Gynecologic Oncology Annual Meeting in Seattle, WA in March, 2025.
MANY THANKS to all of our study participants who generously shared their experience and to clinicians who assisted with recruitment. These efforts will help improve outcomes for other endometrial cancer patients in the future.
For more information on the FEnSI-23 or the PROMOTE Study, please contact Dr. Lari Wenzel at lwenzel@uci.edu.
Supported By
